Statera Biopharma Inc. (STAB)
$0.00
$0.00
(-33.33%)
As on 03-Sep-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-22 Mln
-
ROE
-2.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
-10.4
-
Book Value
$--
-
EPS
$-3.5
-
Face value
--
-
Shares outstanding
71,416,038
10 Years Aggregate
CFO
$-37,647.89 Mln
EBITDA
$-37,531.39 Mln
Net Profit
$-15,955.22 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
| -- | -- | -- | -- | -12.6 | -86.0 | -59.9 |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
| -96.5 | -33.3 | 475.0 | -40.6 | -74.6 | 182.4 | -59.3 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
0.0 | 0.0 | 1.5 | -174.4 | -3,124.7 | 11344.3 | -- | 0.2 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Statera Biopharma (STAB)
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system... and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp. Read more
-
CEO, President & Chairman of the Board
Mr. Michael Kevin Handley
-
CEO, President & Chairman of the Board
Mr. Michael Kevin Handley
-
Headquarters
Fort Collins, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Statera Biopharma (STAB)
What is the current share price of Statera Biopharma Inc (STAB) Today?
The share price of Statera Biopharma Inc (STAB) is $0.00 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Statera Biopharma Inc (STAB) has given a return of -12.64% in the last 3 years.
What is the current PB & PE ratio of Statera Biopharma Inc (STAB)?
Since, TTM earnings of Statera Biopharma Inc (STAB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.02 |
-2.56 |
2021 |
-0.80 |
-54.16 |
2020 |
-6.69 |
-24.21 |
2019 |
-3.02 |
-2.40 |
2018 |
-3.16 |
-7.86 |
What is the 52 Week High and Low of Statera Biopharma Inc (STAB)?
The 52-week high and low of Statera Biopharma Inc (STAB) are Rs 0.00 and Rs 0.00 as of 06-Sep-2026.
What is the market cap of Statera Biopharma Inc (STAB)?
Statera Biopharma Inc (STAB) has a market capitalisation of $ 0 Mln as on 27-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Statera Biopharma Inc (STAB)?
Before investing in Statera Biopharma Inc (STAB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.